Which has preferable earnings and valuation, BVS or ITGR?

Integer has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 2.01 $22.73M $0.77 17.68 Integer $1.85B 2.32 $102.81M $3.66 34.52

Is BVS or ITGR more profitable?

Bioventus has a net margin of 9.36% compared to Integer's net margin of 6.97%. Bioventus' return on equity of 28.08% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% Integer 6.97% 12.79% 6.48%

Does the media favor BVS or ITGR?

In the previous week, Bioventus and Bioventus both had 2 articles in the media. Bioventus' average media sentiment score of 1.87 beat Integer's score of 0.57 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Integer 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, BVS or LIVN?

Bioventus has higher earnings, but lower revenue than LivaNova. Bioventus is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 2.01 $22.73M $0.77 17.68 LivaNova $1.47B 2.89 -$242.47M $3.38 22.83

Is BVS or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% LivaNova 12.82% 16.35% 7.76%

Does the media favor BVS or LIVN?

In the previous week, Bioventus had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for LivaNova. Bioventus' average media sentiment score of 1.87 beat LivaNova's score of 0.46 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive LivaNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IRTC or BVS?

In the previous week, iRhythm Technologies and iRhythm Technologies both had 2 articles in the media. Bioventus' average media sentiment score of 1.87 beat iRhythm Technologies' score of 0.71 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, BVS or PLSE?

Bioventus has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 2.01 $22.73M $0.77 17.68 Pulse Biosciences $350K 10,514.81 -$72.78M -$1.18 N/A

Does the media favor BVS or PLSE?

In the previous week, Pulse Biosciences had 2 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for Pulse Biosciences and 2 mentions for Bioventus. Bioventus' average media sentiment score of 1.87 beat Pulse Biosciences' score of 0.56 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pulse Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BVS or ATRC?

Bioventus has higher revenue and earnings than AtriCure. Bioventus is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 2.01 $22.73M $0.77 17.68 AtriCure $534.53M 5.71 -$11.45M $0.21 285.52

Is BVS or ATRC more profitable?

Bioventus has a net margin of 9.36% compared to AtriCure's net margin of 1.85%. Bioventus' return on equity of 28.08% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% AtriCure 1.85% 2.34% 1.77%

Does the media favor BVS or ATRC?

In the previous week, Bioventus and Bioventus both had 2 articles in the media. Bioventus' average media sentiment score of 1.87 beat AtriCure's score of 0.42 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AtriCure 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bioventus (BVS) Competitors

$13.61 -0.04 (-0.29%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$13.55 -0.06 (-0.43%)

As of 07:05 AM Eastern

Compare

BVS vs. ITGR, LIVN, IRTC, PLSE, and ATRC

Should you buy Bioventus stock or one of its competitors? Bioventus's main competitors and comparable companies include Integer (ITGR), LivaNova (LIVN), iRhythm Technologies (IRTC), Pulse Biosciences (PLSE), and AtriCure (ATRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bioventus compare to Integer?

Bioventus (NASDAQ:BVS) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Integer has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.01	$22.73M	$0.77	17.68
Integer	$1.85B	2.32	$102.81M	$3.66	34.52

In the previous week, Bioventus and Bioventus both had 2 articles in the media. Bioventus' average media sentiment score of 1.87 beat Integer's score of 0.57 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Integer	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Integer has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Bioventus presently has a consensus target price of $16.80, indicating a potential upside of 23.44%. Integer has a consensus target price of $109.86, indicating a potential downside of 13.04%. Given Bioventus' stronger consensus rating and higher probable upside, equities analysts clearly believe Bioventus is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

62.9% of Bioventus shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 1.1% of Integer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bioventus has a net margin of 9.36% compared to Integer's net margin of 6.97%. Bioventus' return on equity of 28.08% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Integer	6.97%	12.79%	6.48%

Summary

Bioventus beats Integer on 9 of the 15 factors compared between the two stocks.

How does Bioventus compare to LivaNova?

Bioventus (NASDAQ:BVS) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

LivaNova has a net margin of 12.82% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
LivaNova	12.82%	16.35%	7.76%

Bioventus has higher earnings, but lower revenue than LivaNova. Bioventus is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.01	$22.73M	$0.77	17.68
LivaNova	$1.47B	2.89	-$242.47M	$3.38	22.83

In the previous week, Bioventus had 1 more articles in the media than LivaNova. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for LivaNova. Bioventus' average media sentiment score of 1.87 beat LivaNova's score of 0.46 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
LivaNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventus has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

62.9% of Bioventus shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bioventus presently has a consensus price target of $16.80, indicating a potential upside of 23.44%. LivaNova has a consensus price target of $84.13, indicating a potential upside of 9.03%. Given Bioventus' stronger consensus rating and higher probable upside, research analysts plainly believe Bioventus is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Bioventus and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.

How does Bioventus compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Bioventus (NASDAQ:BVS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Bioventus has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.93	-$44.55M	-$0.43	N/A
Bioventus	$568.09M	2.01	$22.73M	$0.77	17.68

Bioventus has a net margin of 9.36% compared to iRhythm Technologies' net margin of -1.69%. Bioventus' return on equity of 28.08% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Bioventus	9.36%	28.08%	9.82%

62.9% of Bioventus shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, iRhythm Technologies and iRhythm Technologies both had 2 articles in the media. Bioventus' average media sentiment score of 1.87 beat iRhythm Technologies' score of 0.71 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

iRhythm Technologies has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

iRhythm Technologies presently has a consensus target price of $179.93, suggesting a potential upside of 61.01%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 23.44%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe iRhythm Technologies is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Bioventus beats iRhythm Technologies on 9 of the 16 factors compared between the two stocks.

How does Bioventus compare to Pulse Biosciences?

Bioventus (NASDAQ:BVS) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Pulse Biosciences had 2 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for Pulse Biosciences and 2 mentions for Bioventus. Bioventus' average media sentiment score of 1.87 beat Pulse Biosciences' score of 0.56 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pulse Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 33.5% of Bioventus shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bioventus presently has a consensus price target of $16.80, indicating a potential upside of 23.44%. Pulse Biosciences has a consensus price target of $50.20, indicating a potential downside of 3.42%. Given Bioventus' higher probable upside, research analysts plainly believe Bioventus is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Bioventus has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.01	$22.73M	$0.77	17.68
Pulse Biosciences	$350K	10,514.81	-$72.78M	-$1.18	N/A

Bioventus has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

Bioventus has a net margin of 9.36% compared to Pulse Biosciences' net margin of -6,755.78%. Bioventus' return on equity of 28.08% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Summary

Bioventus beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

How does Bioventus compare to AtriCure?

Bioventus (NASDAQ:BVS) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Bioventus has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

In the previous week, Bioventus and Bioventus both had 2 articles in the media. Bioventus' average media sentiment score of 1.87 beat AtriCure's score of 0.42 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AtriCure	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.9% of Bioventus shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 33.5% of Bioventus shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bioventus presently has a consensus price target of $16.80, suggesting a potential upside of 23.44%. AtriCure has a consensus price target of $53.30, suggesting a potential downside of 11.11%. Given Bioventus' stronger consensus rating and higher probable upside, research analysts plainly believe Bioventus is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Bioventus has higher revenue and earnings than AtriCure. Bioventus is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.01	$22.73M	$0.77	17.68
AtriCure	$534.53M	5.71	-$11.45M	$0.21	285.52

Bioventus has a net margin of 9.36% compared to AtriCure's net margin of 1.85%. Bioventus' return on equity of 28.08% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
AtriCure	1.85%	2.34%	1.77%

Summary

Bioventus beats AtriCure on 10 of the 16 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVS vs. The Competition

Export

Metric	Bioventus	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.15B	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	17.68	25.26	274.08	25.69
Price / Sales	2.01	71.56	638.21	78.99
Price / Cash	10.70	33.02	77.80	52.76
Price / Book	4.93	5.78	10.47	6.32
Net Income	$22.73M	$151.55M	$3.49B	$359.73M
7 Day Performance	7.76%	-0.01%	-0.67%	0.17%
1 Month Performance	-2.92%	-3.53%	-3.17%	-3.27%
1 Year Performance	97.53%	6.37%	15.14%	5.58%

Bioventus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVS Bioventus	4.2908 of 5 stars	$13.61 -0.3%	$16.80 +23.4%	+96.7%	$1.15B	$568.09M	17.68	950	News Coverage Positive News
ITGR Integer	2.653 of 5 stars	$126.35 +0.0%	$109.86 -13.1%	+22.4%	$4.29B	$1.85B	34.52	11,000
LIVN LivaNova	2.5879 of 5 stars	$78.01 +0.3%	$84.13 +7.8%	+43.0%	$4.29B	$1.39B	23.08	3,300	High Trading Volume
IRTC iRhythm Technologies	3.777 of 5 stars	$109.33 -2.2%	$179.93 +64.6%	-36.3%	$3.68B	$747.14M	N/A	2,400	Positive News
PLSE Pulse Biosciences	1.5573 of 5 stars	$53.87 +6.4%	$45.25 -16.0%	+193.7%	$3.58B	$350K	N/A	116	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BVS) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Competitors